title: Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis.
abstract: In Arizona, USA, primary pulmonary coccidioidomycosis accounts for 15%-29% of community-acquired pneumonia. To determine the evolution of symptoms and changes in laboratory values for patients with mild to moderate coccidioidomycosis during 2010-2012, we conducted a prospective 24-week study of patients with primary pulmonary coccidioidomycosis. Of the 36 patients, 16 (44%) were men and 33 (92%) were White. Median age was 53 years, and 20 (56%) had received antifungal treatment at baseline. Symptom scores were higher for patients who received treatment than for those who did not. Median times from symptom onset to 50% reduction and to complete resolution for patients in treatment and nontreatment groups were 9.9 and 9.1 weeks, and 18.7 and 17.8 weeks, respectively. Median times to full return to work were 8.4 and 5.7 weeks, respectively. One patient who received treatment experienced disseminated infection. For otherwise healthy adults with acute coccidioidomycosis, convalescence was prolonged, regardless of whether they received antifungal treatment.
authors.forename: Janis E
authors.initials: JE
authors.lastname: Blair
authors.forename: Yu-Hui H
authors.initials: YH
authors.lastname: Chang
authors.forename: Meng-Ru
authors.initials: MR
authors.lastname: Cheng
authors.forename: Laszlo T
authors.initials: LT
authors.lastname: Vaszar
authors.forename: Holenarasipur R
authors.initials: HR
authors.lastname: Vikram
authors.forename: Robert
authors.initials: R
authors.lastname: Orenstein
authors.forename: Shimon
authors.initials: S
authors.lastname: Kusne
authors.forename: Stanford
authors.initials: S
authors.lastname: Ho
authors.forename: Maria T
authors.initials: MT
authors.lastname: Seville
authors.forename: James M
authors.initials: JM
authors.lastname: Parish
mesh_terms: D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use; D001130:Arizona / Q000453:epidemiology; D003045:Coccidioides / Q000187:drug effects / Q000254:growth & development / Q000472:pathogenicity*; D003047:Coccidioidomycosis / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology*; D017714:Community-Acquired Infections; D003289:Convalescence; D005260:Female; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology*; D011446:Prospective Studies; D012720:Severity of Illness Index
chemical_list: D000935:Antifungal Agents
keywords: Coccidioides; acute pulmonary coccidioidomycosis; antifungal therapy; coccidioidomycosis; community-acquired pneumonia; fungi